MS and Demyelinating Disorders

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital shared thoughts on the promising advancements in the multiple sclerosis field for 2024. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders, and specifically, Duchenne muscular dystrophy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 9, 2024.

The research scientist at Kessler Foundation discussed a recently funded study focused on improving memory and learning deficits in patients with multiple sclerosis by combining a cognitive rehabilitation program with a cycling initiative enriched with virtual reality elements. [WATCH TIME: 7 minutes]

Nananda Col, MD, MPH, MPP, FACP, the president and founder of Shared Decision Making Resources, spoke about usage of the MS-SUPPORT tool in a recent study to foster shared decision-making between patients and clinicians in multiple sclerosis.

The staff neurologist at Cleveland Clinic’s Mellen Center for MS detailed some of the negative impacts issues with access to neurologists and MS care centers can have on patient diagnosis and longterm prognosis. [WATCH TIME: 4 minutes]

Patients with non-P42 MOG-IgG in MOGAD had over three times higher risk of relapsing course than those with P42 MOG-IgG.

Tanuja Chitnis, MD, shares possible course of action if NFL levels begin to rise during treatment.

Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, raise important questions about the extent to which biomarkers can aid in patient care as well as their limitations.

The professor of neurology at Stony Brook University Medical Center discussed the significance of shared decision making in multiple sclerosis care and promising developments in treatment strategies. [WATCH TIME: 3 minutes]

Throughout the 96-week EVOLVE-MS-1 trial, the majority of patients with MS experienced stable outcomes with diroximel fumarate treatment.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke.

In a case report, an HIV-positive patient with active multiple sclerosis showed reduced disease activity with tenofovir-containing antiretrovirals, suggesting potential MS treatment benefits.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 2, 2024.

The founder and executive director of the Sumaira Foundation shared her patient journey living with NMOSD and the progress that has been made in the field over the past decade. [WATCH TIME: 4 minutes]

Marisa McGinley, DO, a staff neurologist at Cleveland Clinic’s Mellen Center for MS Treatment and Research, provided forward thoughts on the healthcare reach of neurologists and care access for patients with multiple sclerosis.

An online shared decision-making tool showed feasibility in most patients with multiple sclerosis, with reported improvements in understanding treatment options and adherence to treatment.

The professor in the department of neurology with McGovern Medical School at UTHealth Houston discussed outcomes of a recent study exploring the specificity of T cells in the spinal fluid of patients diagnosed with multiple sclerosis.

A recent study demonstrated that concomitant sleep apnea syndrome may expedite cognitive decline, particularly in attention and concentration, among patients with multiple sclerosis.

The founder and executive director of the Sumaira Foundation discussed the increasing amount of misdiagnosis in rare diseases such as NMOSD and how it impacts these patients in terms of care and support. [WATCH TIME: 2 minutes]

Take a look at some of the most-anticipated FDA pending approvals expected in 2024 that researchers and clinicians in neurology should keep an eye out on.

Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, talk about the practical use of biomarkers in treatment decision making.

Tanuja Chitnis, MD, explains how higher neurofilament light chain levels can signal disease activity in MS.

The founder and executive director of the Sumaira Foundation shared her patient perspective of Health Canada’s approval of inebilizumab in terms of its implications for patients and how it paves the way for future treatments in NMOSD. [WATCH TIME: 3 minutes]